DNTH
Dianthus Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$101.00-4.36%
Price as of Jul 20, 2026
DNTH profitability
Dianthus Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 94.3%
- EBITDA margin
- -813.0%
- EBIT margin
- —
- Net margin
- -847.5%
- Free cash flow margin
- -9766.8%
Returns
- Return on equity
- -0.9%
- Return on assets
- -0.9%
- Return on invested capital
- -15.9%
- Asset turnover
- 0.00x
Cash efficiency
- Cash from operations
- -$130.3M
- Cash per share
- $20
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.